NCT00422175View on ClinicalTrials.gov

Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

November 30, 2007

Conditions

Healthy

Interventions

DRUG

BAF 312

Trial Locations (1)

Unknown

Novartis, East Hanover

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY